Intermediate dose melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) conditioning therapy and ASCT in relapsed multiple myeloma patients: A single center experience

被引：1

作者：

Scalzulli, Polito Rosario ^{[1
]}

Valvano, Maria Rosa ^{[1
]}

Bodenizza, Carlo C. ^{[1
]}

Carella, Angelo Michele ^{[1
]}

Dell'Olio, Matteo M. ^{[1
]}

Falcone, Antonietta A. P. ^{[1
]}

Greco, Michele Mario ^{[1
]}

La Sala, Antonio A. ^{[1
]}

Mantuano, Francesco F. S. ^{[1
]}

Melillo, Lorella L. ^{[1
]}

Merla, Emanuela E. ^{[1
]}

Nobile, Michele M. ^{[1
]}

Sanpaolo, G. Sanpaolo ^{[1
]}

Cascavilla, Nicola N. ^{[1
]}

机构：

[1] Casa Sollieva Sofferenza Hosp, IRCCS, San Giovanni Rotondo FG, Foggia, Italy

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.5117.5117

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5117

引用

页码：361B / 361B

页数：1

共 50 条

[31] Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients
Boccadoro, M.
Bringhen, S.
Gaidano, G.
Ria, R.
Offidani, M.
Patriarca, F.
Nozzoli, C.
Musto, P.
Petrucci, M.
Palumbo, A. P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[32] SINGLE SHOT MEDIUM DOSE MELPHALAN IN RELAPSED MM PATIENTS: A RETROSPECTIVE, SINGLE CENTER EXPERIENCE
Clissa, C.
Isidori, A.
Loscocco, F.
Gabucci, E.
Malerba, L.
Guiducci, B.
Visani, G.
[J]. HAEMATOLOGICA, 2017, 102 : 800 - 800
[33] BORTEZOMIB-MELPHALAN-PREDNISONE-THALIDOMIDE FOLLOWED BY BORTEZOMIB-THALIDOMIDE MAINTENANCE FOR INITIAL THERAPY OF MULTIPLE MYELOMA: A PROSPECTIVE RANDOMIZED TRIAL
Palumbo, A.
Bringhen, S.
Rossi, D.
Ria, R.
Offidani, M.
Musto, P.
Petrucci, M. T.
Omede, P.
Di Raimondo, F.
Boccadoro, M.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 350 - 350
[34] Longterm Lenalidomide therapy in relapsed or refractory multiple myeloma patients - a single-center experience
Denecke, B.
Bross-Bach, U.
Kanz, L.
Weisel, K.
[J]. ONKOLOGIE, 2010, 33 : 248 - 248
[35] Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
Buadi, Francis K.
Gertz, Morie A.
Laplant, Betsy R.
Halvorson, Alese
Lacy, Martha Q.
Hayman, Suzanne R.
Dingli, David
Kapoor, Prashant
Gonsalves, Wilson I.
Miceli, Teresa
Brandes, Eva
Stafford, Scott L.
Martenson, James A.
Hogan, William J.
Kumar, Shaji K.
[J]. BLOOD, 2016, 128 (22)
[36] Bortezomid in association therapy in relapsed, refractory multiple myeloma: Experience of a single center
Buquicchio, C.
Iacobazzi, A.
Tarantini, G.
Ciuffreda, L.
Desantis, G.
Santorsola, D.
Riezzo, A.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
[37] BORTEZOMIB MAINTENANCE TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA-A SINGLE CENTER EXPERIENCE
Micheva, I.
Dimitrova, S.
Rachev, R.
Varbanov, H.
Mehmed, M.
Gerov, V.
Antonov, A.
Gercheva, L.
[J]. HAEMATOLOGICA, 2016, 101 : 796 - 796
[38] Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
Cerchione, Claudio
Catalano, Lucio
Pareto, Anna Emanuele
Basile, Santina
Marano, Luana
Peluso, Ilaria
Simeone, Luigia
Vitagliano, Orsola
Palmieri, Salvatore
Rocco, Stefano
Romano, Alessandra
Ferrara, Felicetto
Pane, Fabrizio
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S343 - S343
[39] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
Xu, Peipei
Zhou, Rongfu
Xu, Jingyan
Ouyang, Jian
Shao, Xiaoyan
Chen, Bing
[J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
[40] Full dose or reduced dose Melphalan (MEL) for autologous stem cell transplantation (ASCT) in multiple myeloma (MM): a single center analysis on 146 patients
vom Hofe, F.
Muegge, L-O
Scholl, S.
Hilgendorf, I
Sayer, H.
Yomade, O.
Ernst, T.
Hochhaus, A.
von Lilienfeld-Toal, M.
Brioli, A.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 184 - 184

← 1 2 3 4 5 →